EP0767792A4 - Vitronectin-rezeptor antagonisten - Google Patents

Vitronectin-rezeptor antagonisten

Info

Publication number
EP0767792A4
EP0767792A4 EP95926152A EP95926152A EP0767792A4 EP 0767792 A4 EP0767792 A4 EP 0767792A4 EP 95926152 A EP95926152 A EP 95926152A EP 95926152 A EP95926152 A EP 95926152A EP 0767792 A4 EP0767792 A4 EP 0767792A4
Authority
EP
European Patent Office
Prior art keywords
receptor antagonists
vitronectin receptor
vitronectin
antagonists
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95926152A
Other languages
English (en)
French (fr)
Other versions
EP0767792A1 (de
Inventor
Fadia Ali
William Bondinell
William Francis Huffman
M Amparo Lago
Richard Mcculloch Keenan
Chet Kwon
William Henry Miller
Thomas Nguyen
Dennis T Takata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP0767792A1 publication Critical patent/EP0767792A1/de
Publication of EP0767792A4 publication Critical patent/EP0767792A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP95926152A 1994-06-29 1995-06-29 Vitronectin-rezeptor antagonisten Withdrawn EP0767792A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26769594A 1994-06-29 1994-06-29
US267695 1994-06-29
US42893395A 1995-04-25 1995-04-25
US428933 1995-04-25
PCT/US1995/008306 WO1996000730A1 (en) 1994-06-29 1995-06-29 Vitronectin receptor antagonists

Publications (2)

Publication Number Publication Date
EP0767792A1 EP0767792A1 (de) 1997-04-16
EP0767792A4 true EP0767792A4 (de) 2002-11-20

Family

ID=26952569

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95926152A Withdrawn EP0767792A4 (de) 1994-06-29 1995-06-29 Vitronectin-rezeptor antagonisten

Country Status (13)

Country Link
EP (1) EP0767792A4 (de)
JP (1) JPH10504808A (de)
CN (1) CN1156995A (de)
AU (1) AU702661B2 (de)
BR (1) BR9508178A (de)
CA (1) CA2193966A1 (de)
CZ (1) CZ382496A3 (de)
HU (1) HUT76344A (de)
MX (1) MX9700041A (de)
NO (1) NO965608L (de)
NZ (3) NZ290008A (de)
PL (1) PL318199A1 (de)
WO (1) WO1996000730A1 (de)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100423A (en) * 1995-08-30 2000-08-08 G. D. Searle & Co. Amino benzenepropanoic acid compounds and derivatives thereof
MX9801716A (es) 1995-08-30 1998-05-31 Searle & Co Derivados de meta-guanidina, urea, tiourea o acido aminobenzoico azaciclico, como antagonistas de integrina.
US6011029A (en) * 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
ATE212990T1 (de) 1996-03-20 2002-02-15 Hoechst Ag Inhibitoren der knochenresorption und vitronectinrezeptor-antagonisten
ZA972381B (en) * 1996-03-20 1998-12-21 Hoechst Ag Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors
DE19629817A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
DE19629816A1 (de) 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція
EP0946180A4 (de) * 1996-10-07 2003-07-23 Smithkline Beecham Corp Methoden zur stimulierung der knochenbildung
US6482821B2 (en) 1996-12-20 2002-11-19 Hoechst Aktiengellschaft Vitronectin receptor antagonists, their preparation and their use
DE19653647A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
DE19653646A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
DE19653645A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
US6218387B1 (en) 1996-12-20 2001-04-17 Hoechst Aktiengesellschaft Vitronectin receptor anatagonists, their preparation and their use
WO1998043962A1 (en) 1997-03-28 1998-10-08 Du Pont Pharmaceuticals Company Heterocyclic integrin inhibitor prodrugs
WO1999006049A1 (en) * 1997-08-04 1999-02-11 Smithkline Beecham Corporation Integrin receptor antagonists
US6313119B1 (en) 1998-01-23 2001-11-06 Adventis Pharma Deutschland Gmbh Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
WO1999050249A2 (en) 1998-04-01 1999-10-07 Du Pont Pharmaceuticals Company Pyrimidines and triazines as integrin antagonists
US6228985B1 (en) 1998-05-21 2001-05-08 Schering Corporation Derivatives of aminobenzoic and aminobiphenylcarboxylic acids useful as anti-cancer agents
HUP0202648A3 (en) * 1998-06-12 2003-02-28 Sod Conseils Rech Applic Imidazolyl derivatives, pharmaceutical compositions containing them and their use
US6458814B1 (en) * 1998-08-07 2002-10-01 Smithkline Beecham Corporation Vitronectin receptor antagonists
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
US6204282B1 (en) 1998-11-30 2001-03-20 Schering Corporation Benzimidazole compounds that are vitronectin receptor antagonists
CN1161340C (zh) * 1998-11-30 2004-08-11 先灵公司 为玻连蛋白受体拮抗剂的苯并咪唑化合物
US6339083B1 (en) 1998-12-14 2002-01-15 Bayer Aktiengesellschaft Multiheterocyclic pharmAceuticals
EP1140864A2 (de) 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company Pharmazeutische zusammensetzungen, vitronectinrezeptor antagonisten enthaltend
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
EP1150965A4 (de) 1999-02-03 2002-05-15 Merck & Co Inc Benzazepin derivate als alpha-v intgrin rezeptor antagonisten
EP1028114A1 (de) 1999-02-13 2000-08-16 Aventis Pharma Deutschland GmbH Neue Guanidin-Derivate als Inhibitoren der Zelladhäsion
US6271241B1 (en) 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
US6281237B1 (en) 1999-04-02 2001-08-28 Neurogen Corporation N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives
US6380210B1 (en) 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6358949B1 (en) 1999-04-02 2002-03-19 Neurogen Corporation Aryl and hetroaryl fused aminoalkyl-imidazole derivatives: selective modulators of bradykinin B2 receptors
DE60014339T8 (de) * 1999-04-02 2006-04-27 Neurogen Corp., Branford Aryl- und heteroaryl-kondensierte aminoalkyl-imidazol-derivate: selektive modulatoren der gabaa-rezeptoren
US6627624B1 (en) 1999-04-02 2003-09-30 Neurogen Corporation Aryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
EP1165518A2 (de) * 1999-04-02 2002-01-02 Neurogen Corporation Benzimidazol und imidazolopyridin derivate, deren herstellung und deren verwendung als selektive modulatoren von bradykinin b2 (= bk-2) rezeptoren
PL351898A1 (en) 1999-04-06 2003-06-30 Sankyo Co O-substituted derivatives of carboxylic acids
CO5180550A1 (es) * 1999-04-19 2002-07-30 Smithkline Beecham Corp Inhibidores de fab i
AR024158A1 (es) 1999-06-01 2002-09-04 Smithkline Beecham Corp Compuestos antibacterianos
US6762201B1 (en) 1999-10-08 2004-07-13 Affinium Pharmaceuticals, Inc. Fab I inhibitors
ES2231275T3 (es) 1999-10-08 2005-05-16 Affinium Pharmaceuticals, Inc. Inhibidores de fab i.
US6730684B1 (en) 1999-10-08 2004-05-04 Affinium Pharmaceuticals, Inc. Fab I inhibitors
TWI283577B (en) * 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
US6509366B2 (en) 2000-01-18 2003-01-21 Neurogen Corporation Substituted imidazoles as selective modulators of Bradykinin B2 receptors
FR2806082B1 (fr) * 2000-03-07 2002-05-17 Adir Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2001258638A1 (en) 2000-05-26 2001-12-03 Glaxo Group Limited Methods for identifying modulators of the interaction between lap (latency associated peptide) and intergrin alpha.v.beta.3 and medical use thereof
US7566734B2 (en) 2000-08-01 2009-07-28 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Imidazolyl derivatives
JP2004521079A (ja) * 2000-08-29 2004-07-15 ファルマシア・コーポレーション アルファーｖベータ３アンタゴニストとして有用な二環式環系を含有する化合物
FR2822463B1 (fr) 2001-03-21 2004-07-30 Lipha Derives bicycliques de guanidines et leurs applications en therapeutique
JP4387804B2 (ja) 2001-04-06 2009-12-24 アフィニアム・ファーマシューティカルズ・インコーポレイテッド ＦａｂＩ阻害剤
CN1247258C (zh) 2001-04-24 2006-03-29 默克专利有限公司 使用抗血管生成剂和TNFα的联合疗法
US7030150B2 (en) * 2001-05-11 2006-04-18 Trimeris, Inc. Benzimidazole compounds and antiviral uses thereof
FR2829765A1 (fr) * 2001-09-14 2003-03-21 Lipha Derives imidazolylalkoxylarylalcanoiques leurs applications en therapeutique
KR20040058229A (ko) 2001-10-22 2004-07-03 더 스크립스 리서치 인스티튜트 항체 표적화 화합물
FR2847254B1 (fr) 2002-11-19 2005-01-28 Aventis Pharma Sa Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
PE20040804A1 (es) * 2002-12-19 2004-12-31 Boehringer Ingelheim Pharma DERIVADOS DE CARBOXAMIDAS COMO INHIBIDORES DEL FACTOR Xa
FR2870541B1 (fr) * 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
KR20080089489A (ko) 2006-01-18 2008-10-06 메르크 파텐트 게엠베하 인테그린 리간드를 사용하는 암치료용 특이적 요법
EP2054422B1 (de) 2006-07-20 2017-06-14 Debiopharm International SA Acrylamidderivate als fab-i-inhibitoren
EA017864B1 (ru) 2007-01-18 2013-03-29 Мерк Патент Гмбх Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака
WO2008098374A1 (en) 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
EP2221308B1 (de) * 2007-11-16 2013-07-10 Ube Industries, Ltd. Benzazepinonverbindung
JP2012517447A (ja) 2009-02-10 2012-08-02 ザ スクリプス リサーチ インスティチュート 化学的にプログラムされたワクチン接種法
JP5572996B2 (ja) * 2009-05-15 2014-08-20 宇部興産株式会社 ベンズアゼピノン化合物を有効成分として含有する医薬
AU2010252280A1 (en) 2009-05-25 2012-01-19 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
CN102958933B (zh) 2010-06-24 2016-02-03 吉里德科学公司 作为抗病毒药的吡唑并[1,5-a]嘧啶类
ES2647486T3 (es) 2011-12-22 2017-12-21 Gilead Sciences, Inc. Pirazolo[1,5-a]pirimidinas como agentes antivirales
EA027855B1 (ru) 2012-04-17 2017-09-29 Гайлид Сайэнсиз, Инк. Соединения и способы для противовирусной терапии
EP2861608B8 (de) 2012-06-19 2019-06-19 Debiopharm International SA Prodrug-derivate von (e)-n-methyl-n-((3-methylbenzofuran-2-yl) methyl)-3- (7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamid
ES2864079T3 (es) 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
DK3419628T3 (da) 2016-02-26 2021-01-11 Debiopharm Int Sa Medikament til behandling af diabetiske fodinfektioner
CN108707116B (zh) * 2018-07-05 2021-11-30 华侨大学 一种2-烷基取代苯并咪唑衍生物及其制备方法
ES2944535T3 (es) 2019-02-14 2023-06-22 Debiopharm Int Sa Formulación de afabicina, método para preparar la misma
UA129222C2 (uk) 2019-06-14 2025-02-12 Дебіофарм Інтернешнл С.А. Лікарський засіб і його застосування для лікування бактеріальних інфекцій, пов'язаних з біоплівкою
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators
CN120939289B (zh) * 2025-10-15 2025-12-16 上海其胜生物制剂有限公司 一种人工玻璃体及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0385850A2 (de) * 1989-03-03 1990-09-05 Laboratoires Upsa Benzimidazol- und Azabenzimidazol-Derivate, Verfahren zu deren Herstellung, Synthese-Zwischenprodukte, diese enthaltende pharmazeutische Zusammensetzungen, verwendbar bei der Behandlung von Herzgefässerkrankungen und duodenalem Ulcus
EP0468470A1 (de) * 1990-07-23 1992-01-29 Dr. Karl Thomae GmbH Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO1994015608A1 (en) * 1993-01-15 1994-07-21 Agouron Pharmaceuticals, Inc. Hiv protease inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR71915B (de) * 1979-11-27 1983-08-16 Pfizer
US4556660A (en) * 1982-07-12 1985-12-03 Janssen Pharmaceutica N.V. N-(Bicyclic heterocyclyl)-4-piperidinamines
GB8316645D0 (en) * 1983-06-18 1983-07-20 Wyeth John & Brother Ltd Heterocyclic compounds
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
ATE228115T1 (de) * 1991-06-28 2002-12-15 Smithkline Beecham Corp Bizyklische fibrinogenantagonisten
US5250679A (en) * 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
ATE236882T1 (de) * 1992-12-21 2003-04-15 Smithkline Beecham Corp Bicyklische fibrinogen antagoniste
US5300668A (en) * 1993-03-10 1994-04-05 Pfizer Inc. Certain esters of 1-(4-X-methylphenyl)cyclopent-3-ene-1-carboxylic acid, wherein X is a trialkylsilyloxy, bromo or hydroxy group, as intermediates

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0385850A2 (de) * 1989-03-03 1990-09-05 Laboratoires Upsa Benzimidazol- und Azabenzimidazol-Derivate, Verfahren zu deren Herstellung, Synthese-Zwischenprodukte, diese enthaltende pharmazeutische Zusammensetzungen, verwendbar bei der Behandlung von Herzgefässerkrankungen und duodenalem Ulcus
EP0468470A1 (de) * 1990-07-23 1992-01-29 Dr. Karl Thomae GmbH Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO1994015608A1 (en) * 1993-01-15 1994-07-21 Agouron Pharmaceuticals, Inc. Hiv protease inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FELDING-HABERMANN B ET AL: "VITRONECTIN AND ITS RECEPTORS", CURRENT OPINION IN CELL BIOLOGY, CURRENT SCIENCE, LONDON, GB, vol. 5, 1993, pages 864 - 868, XP000885406, ISSN: 0955-0674 *
PASCAL, ROBERT A., JR. ET AL: "Reactions of 2-dichloromethylbenzimidazole with certain primary amines", J. HETEROCYCL. CHEM. ( 1978 ), 15(1), 141-4, XP001094591 *
See also references of WO9600730A1 *

Also Published As

Publication number Publication date
AU3001095A (en) 1996-01-25
HU9603525D0 (en) 1997-02-28
NO965608L (no) 1997-02-27
EP0767792A1 (de) 1997-04-16
NO965608D0 (no) 1996-12-27
CZ382496A3 (en) 1997-12-17
AU702661B2 (en) 1999-02-25
NZ329656A (en) 2000-01-28
WO1996000730A1 (en) 1996-01-11
MX9700041A (es) 1997-04-30
HUT76344A (en) 1997-08-28
NZ329822A (en) 2000-02-28
JPH10504808A (ja) 1998-05-12
CN1156995A (zh) 1997-08-13
NZ290008A (en) 1998-08-26
BR9508178A (pt) 1997-11-18
CA2193966A1 (en) 1996-01-11
PL318199A1 (en) 1997-05-26

Similar Documents

Publication Publication Date Title
ZA955391B (en) Vitronectin receptor antagonists
CY2576B1 (en) Vitronectin receptor antagonists
IL125030A0 (en) Vitronectin receptor antagonists
IL125033A0 (en) Vitronectin receptor antagonists
IL125034A0 (en) Vitronectin receptor antagonists
HU9603525D0 (en) Vironectin receptor antagonists
HU9503402D0 (en) Neurokinin receptor antagonists
IL130760A0 (en) Vitronectin receptor antagonists
EP0763035A4 (de) Endothelin-rezeptor antagonisten
EP1000031A4 (de) Vitronectinrezeptor-antagonist
IL135189A0 (en) Vitronectin receptor antagonist
IL135028A0 (en) Vitronectin receptor antagonists
IL138245A0 (en) Vitronectin receptor antagonists
IL135188A0 (en) Vitronectin receptor antagonist
EP0766684A4 (de) Endothelin-rezeptor antagonisten
EP0768878A4 (de) Endothelin-rezeptor antagonisten
PL346157A1 (en) Vitronectin receptor antagonists
SI0957917T1 (sl) Antagonisti receptorja vitronektina
ZA988562B (en) Vitronectin receptor antagonists
HK1012358A (en) Vitronectin receptor antagonists
ZA978798B (en) Vitronectin receptor antagonists.
GB9812686D0 (en) Vitronectin receptor antagonists
GB9807382D0 (en) Vitronectin receptor antagonists
GB9822331D0 (en) Vitronectin receptor antagonists
GB9810882D0 (en) Vitronectin receptor antagonists

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19961220

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: SI PAYMENT 961220

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07D 519/00 A, 7C 07D 498/04 B, 7C 07D 497/04 B, 7C 07D 495/04 B, 7C 07D 491/04 B, 7C 07D 491/044 B, 7C 07D 491/048 B, 7C 07D 491/052 B, 7C 07D 487/04 B, 7C 07D 473/04 B, 7C 07D 403/12 B

A4 Supplementary search report drawn up and despatched

Effective date: 20021007

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20030403

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20031014

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1012358

Country of ref document: HK